New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cisatracurium besilate 0.669%{relative} equivalent to cisatracurium 0.5% w/v - solution for injection - 5 mg/ml - active: cisatracurium besilate 0.669%{relative} equivalent to cisatracurium 0.5% w/v excipient: benzenesulfonic acid water for injection - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 201 mg (equivalent: cisatracurium, qty 150 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 6.7 mg (equivalent: cisatracurium, qty 5 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 26.8 mg (equivalent: cisatracurium, qty 20 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 67 mg (equivalent: cisatracurium, qty 50 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 13.4 mg (equivalent: cisatracurium, qty 10 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - cisatracurium besilate -